Released : August 18, 2020 07:00 RNS Number : 3824W MaxCyte, Inc. 18 August 2020 CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11 · New parallel cohort will broaden evaluation of MCY-M11 in patients through
Released : July 08, 2020 07:00 RNS Number : 3179S MaxCyte, Inc. 08 July 2020 FOR IMMEDIATE RELEASE APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401 APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based
Released : May 14, 2020 07:00 RNS Number : 8406M MaxCyte, Inc. 14 May 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte to Present Poster Presentation on MCY-M11 at ASCO 2020 Annual Meeting Gaithersburg, Maryland - 14 May 2020: MaxCyte (LSE: MXCT), the global clinical-stage
Released : May 07, 2020 07:00 RNS Number : 1970M MaxCyte, Inc. 07 May 2020 FOR IMMEDIATE RELEASE Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement - Agreement enables Caribou to utilize MaxCyte's ExPERT® platform for
Released : March 24, 2020 07:00 RNS Number : 2942H MaxCyte, Inc. 24 March 2020 FOR IMMEDIATE RELEASE MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement · Agreement enables Allogene, a pioneer in the development of
Released : February 05, 2020 07:00 RNS Number : 9797B MaxCyte, Inc. 05 February 2020 FOR IMMEDIATE RELEASE MaxCyte's CEO to Present Update on Life Sciences Business & First-in-class CARMA™ Cellular Therapies at BIO CEO & Investor Conference in New York Gaithersburg, Maryland - 5
Released : December 04, 2019 07:00 RNS Number : 5710V MaxCyte, Inc. 04 December 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs
Released : November 21, 2019 07:00 RNS Number : 1251U MaxCyte, Inc. 21 November 2019 Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer - Clinical and commercial agreement using MaxCyte's
Released : November 14, 2019 07:00 RNS Number : 3429T MaxCyte, Inc. 14 November 2019 MaxCyte to Present at 2019 Jefferies London Healthcare Conference Gaithersburg, Maryland - 14 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company,
Released : November 07, 2019 07:00 RNS Number : 5671S MaxCyte, Inc. 07 November 2019 MaxCyte to Present at BIO-Europe 2019 Gaithersburg, Maryland - 07 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company , announces that President and
